Novartis to Acquire Excellergy in USD 2 Billion Deal to Boost Food Allergy Pipeline

Under ⁠the agreement, Novartis said it would pay ​up to $2 billion in upfront and milestone payments. The ​transaction is expected to close in the second half of 2026, subject to customary conditions, ​including regulatory approvals.

The transaction ⁠will strengthen ‌Novartis' presence in the market of immunology in food allergy, the ⁠company said. Excellergy's food allergy drug candidate, Exl-111, could support earlier allergy symptom relief, for example.

Novartis had also last week announced its acquisition of a breast cancer drug candidate for up to $3 billion from U.S. biotech firm Synnovation Therapeutics.

In ‌April last year, Novartis said it plans to invest $23 billion to build ​and expand ​its facilities ⁠in the United States through the following half decade.

So far the company has begun construction ​on R&D and manufacturing sites across four states, including California, and expanded its radioligand therapy facilities in Indiana and New Jersey.

Also Read: Entresto Patent Expiry to Weigh on Novartis as Profit Seen Falling in 2026